Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Nov 19, 2024
Product Development
New oral psoriasis mechanism from Protagonist-J&J yields competitive Phase III data
Also in BioCentury’s latest Clinical Report, CRISPR and RNAi face off in ATTR data from Intellia, Alnylam; plus dermatology setbacks for Incyte
BioCentury | Oct 31, 2024
Finance
Axonis advancing KCC2 program with $115M series A
BioCentury’s Venture Report also includes fundings for Evommune, Blue Earth and more
BioCentury | Oct 25, 2024
Finance
Septerna’s GPCRs draw strong demand in $288M IPO
BioCentury’s Financial Report: ProQR’s $75M raise, Seaport’s $225M series B and more
BioCentury | Oct 4, 2024
Finance
Phase I biotechs Septerna, Orum bolster IPO queue
BioCentury’s Public Equity Report also features Caliway’s IPO, Biohaven’s $287.5M follow-on
BioCentury | Apr 23, 2024
Deals
Incyte’s hopes for mast cell program spur $750M Escient takeout
Deal gives Incyte clinical molecules for inflammatory, dermatological disorders
BioCentury | Apr 27, 2023
Emerging Company Profile
Evommune: advancing ex-Dermira assets, screening for new programs using human tissue
Backed with $145M since 2020, the biotech has a Phase IIa molecule for atopic dermatitis, plus at least two preclinical programs
BioCentury | Dec 1, 2022
Finance
With second asset nearing clinic, Escient to test new mast cell targets with $120M series C
Newly backed by NEA, Abingworth and Forge, the biotech is advancing a MRGPRX2 program for urticaria behind its clinical asset for pruritus
Items per page:
1 - 10 of 10